CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Spravato nasal spray is administered by the patient under the supervision ... health care providers have had few options to ...

On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat ...

PH284 increased feelings of hunger and was safe in patients with cancer cachexia, which results in significant weight loss.

Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...

One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it ...

The nasal spray Spravato, which is made from the drug ... What People Are Saying Bill Martin, Ph.D., Global Therapeutic Area Head, Neuroscience, Johnson & Johnson Innovative Medicine said in ...

The FDA has approved esketamine (Spravato) nasal spray as a monotherapy for adults with treatment-resistant depression. This ...

Spravato nasal spray is administered by the patient under ... to offer patients much-needed symptom improvement," Bill Martin, Ph.D., Global Therapeutic Area Head, Neuroscience, Johnson & Johnson ...